Second 'Drugs Made In America' SPAC Raises $500M In IPO
Drugs Made In America Acquisition II, a special purpose acquisition company planning to target companies in the pharmaceutical industry, began trading publicly on Thursday after pricing a $500 million initial public...To view the full article, register now.
Already a subscriber? Click here to view full article